You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH: www.schoenherr.eu
Schoenherr's healthcare group draws on a breadth of experience across the firm's practice areas. We combine specialist knowledge and experience with the insights and track-record of our market-leading transactional practice.
Our healthcare & life sciences team covers a wide range of subjects, including pharmaceuticals, biochemistry, chemicals, e-health, cosmetics, medical devices, toys, tobacco products, food and feed.
Partners Andreas Natterer and Paweł Halwa lead and coordinate the Schoenherr expert team. We act for and advise all stakeholders active in the healthcare, life sciences, biotech and pharma sectors. Areas of particular expertise are regulatory life sciences work and transactional advice regarding targets in the healthcare and life sciences industry.
Working closely and in integrated teams with specialists in:
Our full-service offering in the healthcare & life sciences sector covers:
Our advisory covers inter alia:
From supplements to services: accessibility now legally required in digital healthcare
Austria's Accessibility Act (Barrierefreiheitsgesetz – BaFG), implementing Directive (EU) 2019/882 into national law, has been in force since 28 June 2025. Its main objective is to establish mandatory accessibility standards for certain products and services, ensuring that all people – especially those with disabilities – can access and use them without barriers. This introduces important obligations and practical implications for businesses, including those operating in the consumer healthcare sector.
03 July 2025
austria bulgaria poland czech republic romania
S.Rosenthaler A.Natterer M.Voldánová M.Demirev H.Hadzhiiliev E.Todorova A.Minioti D.Rutecka P.Podsiedlik P.Klimek-Woźniak O.Grecu I.Sava
to the point: Healthcare & Life Sciences Q2/2025
Welcome to the very first edition of to the point: Healthcare & Life Sciences – a new format designed to keep you informed about legal and regulatory developments shaping the sector across Europe.
Pharmaceuticals: challenges in entering Bulgaria's wholesale medicinal market
The pharmaceutical market in Bulgaria is a dynamic and rapidly growing sector, driven by increasing healthcare demands and a robust regulatory framework. It features a competitive mix of local and international players, with a significant presence of generic and innovative medicinal products. The push for generic medicinal products has also led to a rise in previously limited patent-related cases and revocation proceedings. However, the wholesale market remains crucial for ensuring the availability and distribution of medicinal products throughout the country.
The coronavirus presents us with completely new challenges. With the coronavirus info corner we aim to provide specifics about certain legal aspects surrounding Covid-19.
Schoenherr's healthcare & life sciences team consists of experienced lawyers across all our CEE offices.